Tumor-intrinsic PHGDH inhibition sensitizes colorectal cancer to PD-1 blockade via α-ketoglutarate-mediated macrophage reprogramming.
Metabolic reprogramming of tumor cells profoundly shapes the tumor microenvironment and contributes to immunotherapy resistance in colorectal cancer (CRC). Here, we identify phosphoglycerate dehydrogenase (PHGDH), a rate-limiting enzyme in de novo serine biosynthesis, as a metabolic regulator of antitumor immunity. In...